Abstract OBJECTIVE: To investigate the Mycoplasma pneumoniae (MP) infection and drug resistance in children with respiratory tract infection and to provide a rational basis for the clinical diagnosis and treatment of MP infection. METHODS: Throat swabs were collected from 3529 children with respiratory tract infection, who visited the pediatric outpatient department or received treatment in the pediatric ward of our hospital from September 2010 to September 2011. The swabs were cultured to detect MP. The drug sensitivity of MP to azithromycin, roxithromycin, erythromycin, acetylspiramycin and clarithromycin was evaluated. RESULTS: Of the 3529 children with respiratory tract infection, 1026 (29.07%) were MP-positive. There were cases of MP infection in all four seasons of the year but infection rates in summer and autumn were significantly higher than in spring and winter (P0.05). The infection rate was negatively correlated with age in these children, and there were significant differences in the infection rate among all age groups (P<0.05). For macrolide antibiotics suitable for children, the cultured MP developed the highest resistance to roxithromycin, followed by erythromycin, acetylspiramycin, clarithromycin, and azithromycin, with significant differences among them (P<0.01). CONCLUSIONS: MP infection rate is very high among children with respiratory tract infection. The incidence of MP infection is relatively low among school-age children and children are more susceptible to MP infection in summer and autumn than in spring and winter. Throat swabs should be cultured and drug sensitivity tests should be performed as early as possible in children with respiratory tract infection, so that proper intervention can be undertaken in time to reduce drug-resistant strains of MP.
YANG Ai-Mei,SONG Jian-Hui,HUANG Rong et al. Mycoplasma pneumoniae infection and drug resistance in children: an analysis of 1026 cases[J]. CJCP, 2013, 15(7): 522-525.
YANG Ai-Mei,SONG Jian-Hui,HUANG Rong et al. Mycoplasma pneumoniae infection and drug resistance in children: an analysis of 1026 cases[J]. CJCP, 2013, 15(7): 522-525.
［3］Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with communityacquired pneumonia［J］. Antimicrob Agents Chemother, 2008, 52(1): 348-350.
［4］Pereyre S, Charron A, Renaudin H, Bebeaer C, Bebear CM. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years［J］. J Clin Microbiol, 2007, 45(11): 3534-3539.
［5］Principi N, Esposito S. Mycoplasma pneumoniae and chlamydia pneumoniae cause lower respiratory tract diease in paediatric patients［J］. Curr Opin Infect Dis, 2002, 15(3): 295-300.
［6］Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical of community-acquired pneumonia in hospitalized children［J］. Pediartics, 2004, 113(4): 701-707.
［10］Okazaki N, Ohya H, Sasaki T. Mycoplasma pneumonia isolated from patients with respiratory infection in kanagawa prefecture in 1976-2006: emergence of macrolide-resistant strains［J］. Jpn J Infect Dis, 2007, 60(5): 325-326.
